Clobazam

ANDA 209808, held by Pharmazone. Clobazam.

As of Nov 15, 2026, ANDA 209808 (Clobazam), held by Pharmazone, was first approved by FDA on Oct 22, 2018, with 3 approved supplements and 0 published complete response letters.

First approved: Oct 22, 2018
Review: Standard
Supplements approved: 3
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 4 submissions below

Date	Submission	Status	Documents
Oct 22, 2018	Original application	Approved	None posted

Products

2 strengths and forms


Clobazam10MG · tablet;oral	Clobazam	Rx
Clobazam20MG · tablet;oral	Clobazam	Rx

All 4 submissions, including labeling and manufacturing supplements


Jun 10, 2024	Supplement 3Labeling · Standard review	Approved	None posted
May 3, 2023	Supplement 2Labeling · Standard review	Approved	None posted
Oct 25, 2021	Supplement 1Labeling · Standard review	Approved	None posted
Oct 22, 2018	Original application	Approved	None posted

Identifiers

Application: ANDA 209808
Drugs@FDA: Overview at FDA
Company: Pharmazone

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters